Kyverna Therapeutics reported cash from operations of -$40.30M and free cash flow of -$38.76M for the quarter ended Jun 2026, down 26.0% year over year. This cash flow statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Net Income | -11.14M | -13.08M | -15.45M | -20.64M | -26.67M | -28.78M | -34.45M | -37.49M | -44.61M | -42.06M | -36.73M | -37.82M | -39.71M | -38.30M |
| Share-based Compensation | 0.47M | 0.45M | 0.52M | 0.78M | 4.23M | 4.17M | 7.11M | 1.38M | 7.98M | 9.94M | 28.50M | 2.70M | 39.50M | 33.00M |
| Asset Writedowns and Impairment | 0.65M | |||||||||||||
| Cash from Operations | -11.46M | -11.26M | -11.13M | -18.56M | -25.52M | -24.18M | -27.49M | -37.11M | -44.91M | -31.98M | -43.28M | -33.53M | -41.60M | -40.30M |
| Depreciation, Depletion & Amortization | ||||||||||||||
| Amortizatization of Intangibles | 0.08M | -0.01M | 0.44M | 0.60M | 0.28M | 2.25M | 2.89M | 2.24M | 2.11M | 1.84M | 1.57M | 1.37M | 0.73M | 0.19M |
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.39M | 0.41M | 0.44M | 0.46M | 0.48M | 0.53M | 0.56M | 0.56M | 0.50M | 0.52M | 0.41M | 0.37M | 0.35M | 0.43M |
| Change in Working Capital | ||||||||||||||
| Change in Account Payables | 0.10M | 0.49M | 0.51M | 2.98M | 3.07M | -2.10M | 5.07M | -5.30M | 3.78M | 1.41M | -6.80M | -0.89M | 6.28M | -8.65M |
| Change in Accured Expenses | -0.78M | 0.50M | 0.72M | 0.96M | -1.45M | 1.36M | 1.72M | 0.44M | -1.80M | 1.89M | 1.99M | 3.03M | -6.88M | 2.37M |
| Other Working Capital Changes | -0.34M | 1.24M | -2.12M | -0.46M | 2.57M | -3.70M | -0.62M | -0.65M | -0.96M | -1.01M | -0.52M | -0.84M | -0.50M | -0.73M |
| Investing Activities | ||||||||||||||
| Capital Expenditures | 0.43M | -0.57M | 0.42M | 1.56M | 0.54M | 1.03M | 0.10M | 0.53M | 0.52M | -0.01M | 0.96M | -0.34M | 0.01M | -1.55M |
| Change in Acquisitions & Divestments | 13.68M | 33.00M | 23.00M | 13.00M | 138.30M | 157.00M | 86.70M | 124.10M | 95.70M | 99.20M | 65.70M | 68.60M | ||
| Cash from Investing Activities | 13.65M | -0.00M | -54.12M | 31.68M | -122.88M | -67.92M | 0.68M | 29.22M | 5.58M | 29.17M | 22.56M | -17.29M | -50.20M | 36.13M |
| Financing Activities | ||||||||||||||
| Other financing activities | 0.02M | 0.04M | 0.31M | 0.28M | 341.17M | 0.00M | 1.65M | 97.31M | 0.24M | 1.65M | ||||
| Change in Capital Stock | ||||||||||||||
| Net Shares Issued and Repurchased | 0.29M | 4.42M | 0.69M | 4.08M | 1.85M | |||||||||
| Net Equity Issued and Repurchased | 34.84M | 3.60M | ||||||||||||
| Misc. | ||||||||||||||
| Cash from Financing Activities | -0.14M | 24.91M | 34.79M | -1.43M | 338.05M | -0.57M | -0.15M | -0.21M | -0.41M | -0.65M | 1.49M | 140.74M | -0.10M | 3.79M |
| Change in Cash | 2.05M | 13.65M | -30.46M | 11.68M | 189.65M | -92.67M | -26.96M | -8.05M | -39.75M | -3.43M | -19.28M | 89.93M | -91.90M | -0.39M |
| Free Cash Flow | -11.89M | -10.69M | -11.55M | -20.12M | -26.07M | -25.20M | -27.59M | -37.64M | -45.43M | -31.98M | -44.24M | -33.19M | -41.60M | -38.76M |
| Net Cash Flow | 2.05M | 13.65M | -30.46M | 11.68M | 189.65M | -92.67M | -26.96M | -8.10M | -39.75M | -3.47M | -19.24M | 89.93M | -91.90M | -0.39M |